Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 276

1.

An iPSC-Derived Myeloid Lineage Model of Herpes Virus Latency and Reactivation.

Poole E, Huang CJZ, Forbester J, Shnayder M, Nachshon A, Kweider B, Basaj A, Smith D, Jackson SE, Liu B, Shih J, Kiskin FN, Roche K, Murphy E, Wills MR, Morrell NW, Dougan G, Stern-Ginossar N, Rana AA, Sinclair J.

Front Microbiol. 2019 Oct 9;10:2233. doi: 10.3389/fmicb.2019.02233. eCollection 2019.

2.

Advances in the treatment of cytomegalovirus.

Krishna BA, Wills MR, Sinclair JH.

Br Med Bull. 2019 Sep 19;131(1):5-17. doi: 10.1093/bmb/ldz031.

3.

Generation, maintenance and tissue distribution of T cell responses to human cytomegalovirus in lytic and latent infection.

Jackson SE, Sedikides GX, Okecha G, Wills MR.

Med Microbiol Immunol. 2019 Aug;208(3-4):375-389. doi: 10.1007/s00430-019-00598-6. Epub 2019 Mar 20. Review.

4.

Distinct Roles of Extracellular Domains in the Epstein-Barr Virus-Encoded BILF1 Receptor for Signaling and Major Histocompatibility Complex Class I Downregulation.

Fares S, Spiess K, Olesen ETB, Zuo J, Jackson S, Kledal TN, Wills MR, Rosenkilde MM.

MBio. 2019 Jan 15;10(1). pii: e01707-18. doi: 10.1128/mBio.01707-18.

5.

Utilizing TAPBPR to promote exogenous peptide loading onto cell surface MHC I molecules.

Ilca FT, Neerincx A, Wills MR, de la Roche M, Boyle LH.

Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):E9353-E9361. doi: 10.1073/pnas.1809465115. Epub 2018 Sep 13.

6.

No evidence of ongoing evolution in replication competent latent HIV-1 in a patient followed up for two years.

Mok HP, Norton NJ, Hirst JC, Fun A, Bandara M, Wills MR, Lever AML.

Sci Rep. 2018 Feb 8;8(1):2639. doi: 10.1038/s41598-018-20682-w.

7.

Innovations in the quantitative virus outgrowth assay and its use in clinical trials.

Norton NJ, Fun A, Bandara M, Wills MR, Mok HP, Lever AML.

Retrovirology. 2017 Dec 21;14(1):58. doi: 10.1186/s12977-017-0381-2. Review.

8.

Latency-Associated Expression of Human Cytomegalovirus US28 Attenuates Cell Signaling Pathways To Maintain Latent Infection.

Krishna BA, Poole EL, Jackson SE, Smit MJ, Wills MR, Sinclair JH.

MBio. 2017 Dec 5;8(6). pii: e01754-17. doi: 10.1128/mBio.01754-17.

9.

Human Cytomegalovirus Delays Neutrophil Apoptosis and Stimulates the Release of a Prosurvival Secretome.

Pocock JM, Storisteanu DML, Reeves MB, Juss JK, Wills MR, Cowburn AS, Chilvers ER.

Front Immunol. 2017 Sep 25;8:1185. doi: 10.3389/fimmu.2017.01185. eCollection 2017.

10.

Latent Cytomegalovirus (CMV) Infection Does Not Detrimentally Alter T Cell Responses in the Healthy Old, But Increased Latent CMV Carriage Is Related to Expanded CMV-Specific T Cells.

Jackson SE, Sedikides GX, Okecha G, Poole EL, Sinclair JH, Wills MR.

Front Immunol. 2017 Jun 26;8:733. doi: 10.3389/fimmu.2017.00733. eCollection 2017.

11.

CMV immune evasion and manipulation of the immune system with aging.

Jackson SE, Redeker A, Arens R, van Baarle D, van den Berg SPH, Benedict CA, Čičin-Šain L, Hill AB, Wills MR.

Geroscience. 2017 Jun;39(3):273-291. doi: 10.1007/s11357-017-9986-6. Epub 2017 Jun 24.

12.

Modulation of Human Leukocyte Antigen-C by Human Cytomegalovirus Stimulates KIR2DS1 Recognition by Natural Killer Cells.

van der Ploeg K, Chang C, Ivarsson MA, Moffett A, Wills MR, Trowsdale J.

Front Immunol. 2017 Mar 29;8:298. doi: 10.3389/fimmu.2017.00298. eCollection 2017.

13.
14.
15.

Human Cytomegalovirus (HCMV)-Specific CD4+ T Cells Are Polyfunctional and Can Respond to HCMV-Infected Dendritic Cells In Vitro.

Jackson SE, Sedikides GX, Mason GM, Okecha G, Wills MR.

J Virol. 2017 Feb 28;91(6). pii: e02128-16. doi: 10.1128/JVI.02128-16. Print 2017 Mar 15.

16.

Corrigendum: The Expression of Human Cytomegalovirus MicroRNA MiR-UL148D during Latent Infection in Primary Myeloid Cells Inhibits Activin A-triggered Secretion of IL-6.

Lau B, Poole E, Krishna B, Montanuy I, Wills MR, Murphy E, Sinclair J.

Sci Rep. 2016 Sep 26;6:33771. doi: 10.1038/srep33771. No abstract available.

17.

The Expression of Human Cytomegalovirus MicroRNA MiR-UL148D during Latent Infection in Primary Myeloid Cells Inhibits Activin A-triggered Secretion of IL-6.

Lau B, Poole E, Krishna B, Sellart I, Wills MR, Murphy E, Sinclair J.

Sci Rep. 2016 Aug 5;6:31205. doi: 10.1038/srep31205.

18.

Transient activation of human cytomegalovirus lytic gene expression during latency allows cytotoxic T cell killing of latently infected cells.

Krishna BA, Lau B, Jackson SE, Wills MR, Sinclair JH, Poole E.

Sci Rep. 2016 Apr 19;6:24674. doi: 10.1038/srep24674.

20.

How understanding immunology contributes to managing CMV disease in immunosuppressed patients: now and in future.

Sissons JG, Wills MR.

Med Microbiol Immunol. 2015 Jun;204(3):307-16. doi: 10.1007/s00430-015-0415-0. Epub 2015 Apr 21. Review.

PMID:
25896527
21.

Ribosome profiling reveals pervasive translation outside of annotated protein-coding genes.

Ingolia NT, Brar GA, Stern-Ginossar N, Harris MS, Talhouarne GJ, Jackson SE, Wills MR, Weissman JS.

Cell Rep. 2014 Sep 11;8(5):1365-79. doi: 10.1016/j.celrep.2014.07.045. Epub 2014 Aug 21.

22.

The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies?

Wills MR, Poole E, Lau B, Krishna B, Sinclair JH.

Cell Mol Immunol. 2015 Mar;12(2):128-38. doi: 10.1038/cmi.2014.75. Epub 2014 Aug 18. Review.

23.

Diverse specificities, phenotypes, and antiviral activities of cytomegalovirus-specific CD8+ T cells.

Jackson SE, Mason GM, Okecha G, Sissons JG, Wills MR.

J Virol. 2014 Sep;88(18):10894-908. doi: 10.1128/JVI.01477-14. Epub 2014 Jul 9.

24.

Human cytomegalovirus latency-associated proteins elicit immune-suppressive IL-10 producing CD4⁺ T cells.

Mason GM, Jackson S, Okecha G, Poole E, Sissons JG, Sinclair J, Wills MR.

PLoS Pathog. 2013;9(10):e1003635. doi: 10.1371/journal.ppat.1003635. Epub 2013 Oct 10.

25.

CMV and Immunosenescence: from basics to clinics.

Solana R, Tarazona R, Aiello AE, Akbar AN, Appay V, Beswick M, Bosch JA, Campos C, Cantisán S, Cicin-Sain L, Derhovanessian E, Ferrando-Martínez S, Frasca D, Fulöp T, Govind S, Grubeck-Loebenstein B, Hill A, Hurme M, Kern F, Larbi A, López-Botet M, Maier AB, McElhaney JE, Moss P, Naumova E, Nikolich-Zugich J, Pera A, Rector JL, Riddell N, Sanchez-Correa B, Sansoni P, Sauce D, van Lier R, Wang GC, Wills MR, Zieliński M, Pawelec G.

Immun Ageing. 2012 Oct 31;9(1):23. doi: 10.1186/1742-4933-9-23.

26.

The RNA-binding E3 ubiquitin ligase MEX-3C links ubiquitination with MHC-I mRNA degradation.

Cano F, Bye H, Duncan LM, Buchet-Poyau K, Billaud M, Wills MR, Lehner PJ.

EMBO J. 2012 Aug 29;31(17):3596-606. doi: 10.1038/emboj.2012.218. Epub 2012 Aug 3.

27.

Human cytomegalovirus latency alters the cellular secretome, inducing cluster of differentiation (CD)4+ T-cell migration and suppression of effector function.

Mason GM, Poole E, Sissons JG, Wills MR, Sinclair JH.

Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14538-43. doi: 10.1073/pnas.1204836109. Epub 2012 Jul 23.

28.

Efficient human cytomegalovirus reactivation is maturation dependent in the Langerhans dendritic cell lineage and can be studied using a CD14+ experimental latency model.

Huang MM, Kew VG, Jestice K, Wills MR, Reeves MB.

J Virol. 2012 Aug;86(16):8507-15. doi: 10.1128/JVI.00598-12. Epub 2012 May 30.

29.

Defining hypercalciuria in nephrolithiasis.

Pak CY, Sakhaee K, Moe OW, Poindexter J, Adams-Huet B, Pearle MS, Zerwekh JE, Preminger GM, Wills MR, Breslau NA, Bartter FC, Brater DC, Heller HJ, Odvina CV, Wabner CL, Fordtran JS, Oh M, Garg A, Harvey JA, Alpern RJ, Snyder WH, Peters PC.

Kidney Int. 2011 Oct;80(7):777-82. doi: 10.1038/ki.2011.227. Epub 2011 Jul 20. Review.

30.

Immunobiology and host response.

Wills MR, Carmichael AJ, Sinclair J, Sissons JP.

In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007. Chapter 43.

31.

Human cytomegalovirus immunity and immune evasion.

Jackson SE, Mason GM, Wills MR.

Virus Res. 2011 May;157(2):151-60. doi: 10.1016/j.virusres.2010.10.031. Epub 2010 Nov 5. Review.

PMID:
21056604
32.

Intracellular sequestration of the NKG2D ligand ULBP3 by human cytomegalovirus.

Bennett NJ, Ashiru O, Morgan FJ, Pang Y, Okecha G, Eagle RA, Trowsdale J, Sissons JG, Wills MR.

J Immunol. 2010 Jul 15;185(2):1093-102. doi: 10.4049/jimmunol.1000789. Epub 2010 Jun 7.

33.

NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142.

Ashiru O, Bennett NJ, Boyle LH, Thomas M, Trowsdale J, Wills MR.

J Virol. 2009 Dec;83(23):12345-54. doi: 10.1128/JVI.01175-09. Epub 2009 Sep 30.

34.

Dynamics of T cell memory in human cytomegalovirus infection.

Waller EC, Day E, Sissons JG, Wills MR.

Med Microbiol Immunol. 2008 Jun;197(2):83-96. doi: 10.1007/s00430-008-0082-5. Epub 2008 Feb 27. Review.

PMID:
18301918
35.

Differential costimulation through CD137 (4-1BB) restores proliferation of human virus-specific "effector memory" (CD28(-) CD45RA(HI)) CD8(+) T cells.

Waller EC, McKinney N, Hicks R, Carmichael AJ, Sissons JG, Wills MR.

Blood. 2007 Dec 15;110(13):4360-6. Epub 2007 Sep 18.

PMID:
17878400
36.
37.

Regulation of NKG2D ligand gene expression.

Eagle RA, Traherne JA, Ashiru O, Wills MR, Trowsdale J.

Hum Immunol. 2006 Mar;67(3):159-69. Epub 2006 Apr 17.

PMID:
16698438
39.

Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis.

Wills MR, Ashiru O, Reeves MB, Okecha G, Trowsdale J, Tomasec P, Wilkinson GW, Sinclair J, Sissons JG.

J Immunol. 2005 Dec 1;175(11):7457-65.

40.
41.

Effects of Chlamydia trachomatis infection on the expression of natural killer (NK) cell ligands and susceptibility to NK cell lysis.

Hook CE, Telyatnikova N, Goodall JC, Braud VM, Carmichael AJ, Wills MR, Gaston JS.

Clin Exp Immunol. 2004 Oct;138(1):54-60.

42.

Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation.

Gandhi MK, Wills MR, Sissons JG, Carmichael AJ.

Blood Rev. 2003 Dec;17(4):259-64. Review.

PMID:
14556781
43.

Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantation.

Gandhi MK, Wills MR, Okecha G, Day EK, Hicks R, Marcus RE, Sissons JG, Carmichael AJ.

Blood. 2003 Nov 1;102(9):3427-38. Epub 2003 Jul 17.

PMID:
12869514
44.

Human cytomegalovirus and immunopathology.

Sissons JG, Carmichael AJ, McKinney N, Sinclair JH, Wills MR.

Springer Semin Immunopathol. 2002;24(2):169-85. Review. No abstract available.

PMID:
12503063
45.

Vaccines against persistent DNA virus infections.

Wills MR, Carmichael AJ, Sissons JG.

Br Med Bull. 2002;62:125-38. Review.

PMID:
12176855
46.

Latency and reactivation of human cytomegalovirus.

Sissons JG, Bain M, Wills MR.

J Infect. 2002 Feb;44(2):73-7. Review.

PMID:
12076064
48.

Status of Cytomegalovirus Prevention and Treatment in 2000.

Zaia JA, Sissons JG, Riddell S, Diamond DJ, Wills MR, Carmichael AJ, Weekes MP, Gandhi M, La Rosa C, Villacres M, Lacey S, Markel S, Sun J.

Hematology Am Soc Hematol Educ Program. 2000:339-355.

PMID:
11701550
49.

Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors.

Gillespie GM, Wills MR, Appay V, O'Callaghan C, Murphy M, Smith N, Sissons P, Rowland-Jones S, Bell JI, Moss PA.

J Virol. 2000 Sep;74(17):8140-50.

50.

Analysis of cytotoxic T-cell responses to human cytomegalovirus infection.

Wills MR, Sissons JG.

Methods Mol Med. 2000;33:115-27. doi: 10.1385/1-59259-244-9:115.

PMID:
21340956

Supplemental Content

Loading ...
Support Center